Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Download Click on the link below to be directed to study information at
Document related concepts
no text concepts found
Transcript
Click on the link below to be directed to study information at “ClinicalTrials.Gov” the US National Institutes of Health website. Condition Active Research Studies St. Luke's Contact ST. LUKE’S CONTACT ANATOMICAL SITE RESEARCH BASE & REFERENCE # STUDY TITLE Cancer: Diffuse Large B Cell Lymphoma ECOG-E1412 NCT01856192 Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma Lisa K. 218-249-6938, [email protected] Cancer: Chronic Lymphocytic Leukemia Alliance A041202 NCT01886872 A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL) Lisa K. 218-249-6938, [email protected] Cancer: BRAIN Alliance N1174 NCT 01648348 Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme Lisa K. 218-249-6938, [email protected] BRAIN NRG- BN001 NCT02179086 Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Lisa K. 218-249-6938, [email protected] BRAIN Alliance A071102 NCT02152982 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation Lisa K. 218-249-6938, [email protected] Cancer: HEAD & NECK/ORAL RTOG 0920 NCT00956007 Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Lisa K. 218-249-6938, [email protected] HEAD/NECK/ORAL Recurrent/metastatic MERCK MK-3475-048-00 NCT02358031 A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Lisa C, RN 218-249-2567 [email protected] Cancer: BREAST SWOG S1007 Rx PONDER NCT01272037 A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. Lisa K. 218-249-6938, [email protected] BREAST SWOG S1207 NCT01674140 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of EVEROLIMUS in Patients with HighRisk, Hormone Receptor-Positive AND HER2/neu Negative Breast Cancer. Lisa K. 218-249-6938, [email protected] BREAST Medication-related Muscle Pain CTSU E1Z11 NCT01824836 A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) Lisa K. 218-249-6938, [email protected] Cancer: LUNG NSCLC Alliance A151216 NCT02194738 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Lisa K. 218-249-6938, [email protected] NSCLC Alliance A081105 NCT02193282 Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) Lisa K. 218-249-6938, [email protected] NSCLC CTSU E4512 NCT02201992 A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein Lisa K. 218-249-6938, [email protected] NSCLC Stage III NRG LU001 NCT02186847 Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC Lisa K. 218-249-6938, [email protected] NSCLC Stage IIIB/IV SYNTA -9090-14 NCT01798485 A Randomized, Phase 3 Study of Ganetespib in Combination with Docetaxel versus Docetaxel Alone in Patients with Advanced Non-Small-Cell Lung Adenocarcinoma Lisa C, RN 218-249-2567 [email protected] NSCLC Metastatic MERCK MK3475-024-00 NCT02142738 A Randomized Open-Label Phase III Trial of MK-3475 versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer Lisa C, RN 218-249-2567 [email protected] Cancer: COLORECTAL Stage III CALGB 80702 NCT01150045 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Lisa K. 218-249-6938, [email protected] COLORECTAL Metastatic SWOG S1406 NCT02164916 Randomized Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer Lisa K. 218-249-6938, [email protected] Cancer: PROSTATE RTOG 0924 NCT01368588 Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial Lisa K. 218-249-6938, [email protected] Intermediate-Risk RTOG 0815 NCT00936390 A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With IntermediateRisk Prostate Cancer Lisa K. 218-249-6938, [email protected] PROSTATE Recurrent RTOG 0534 NCT00567580 Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer(SPORT) Lisa K. 218-249-6938, [email protected] PROSTATE Metastatic Alliance A031201 NCT01949337 Phase III Trial of Enzalutamide (NSC #766085) versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer Lisa K. 218-249-6938, [email protected] Intermediate-Risk, High-Risk PROSTATE PROSTATE Aragon- ARN-509 NCT01946204 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer Lisa C, RN 218-249-2567 [email protected] Cancer: GYN Ovary/peritoneal/fallopian tube Janssen ET743-OVC-3006 NCT01846611 A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of AdvancedRelapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Lisa C, RN 218-249-2567 [email protected]
Related documents